Schnitzler Syndrome — Structured Data

AI-optimized single page. All data for Schnitzler Syndrome in dense, structured format. Last updated: 2026-03-09.

View interactive disease hub · View all sources

Key Statistics

Total reported cases: 748
Mean onset age: 53 years
Onset range: 13–71 years
Sex ratio (M:F): 1.76:1
Diagnostic delay: ~5 years
Discovered: 1972 (Liliane Schnitzler)
Prevalence: <1/1,000,000
Classification: autoinflammatory, hematologic
Pathophysiology: partially understood
Treatment status: effective options available
Genetic basis: under investigation
Aliases: Schnitzler's Syndrome, SchS

Symptoms (13)

Symptom	Frequency	Severity	Category	Description
Chronic urticarial rash	100%	cardinal	dermatologic	Non-pruritic or mildly pruritic wheals, often worse in evening. Individual lesions last <24 hours. Neutrophilic dermal infiltrate on biopsy.
Monoclonal IgM gammopathy	100%	cardinal	laboratory	Obligate diagnostic criterion. IgM-kappa in ~94% of cases. M-spike often low (median 0.6 g/dL). SPEP alone may miss it in 51% — immunofixation required.
Recurrent fever	85%	major	systemic	Intermittent fever >38°C, often in evening. Resolves within hours of anakinra.
Bone pain	70%	major	musculoskeletal	Predominantly distal femora and proximal tibiae ('hot knees'). Osteosclerotic lesions on imaging in 64%.
Arthralgia	75%	major	musculoskeletal	Joint pain without destructive arthropathy. Large joints most commonly affected.
Fatigue	80%	major	systemic	Often severe and debilitating. Correlates with inflammatory marker levels.
Elevated CRP	95%	major	laboratory	Consistently elevated C-reactive protein reflecting systemic inflammation. Normalizes rapidly with IL-1 blockade.
Elevated ESR	90%	major	laboratory	Erythrocyte sedimentation rate >20 mm/h. Minor criterion in Lipsker criteria.
Leukocytosis	65%	minor	laboratory	White blood cell count >10,000/μL with neutrophilia.
Weight loss	40%	minor	systemic	Unintentional weight loss due to chronic inflammation.
Lymphadenopathy	30%	minor	systemic	Palpable lymph nodes, usually mild.
Hepatomegaly/splenomegaly	25%	minor	systemic	Organ enlargement reflecting systemic inflammation.
Myalgia	50%	minor	musculoskeletal	Muscle pain, often accompanying fever episodes.

Molecular Pathway (13 molecules)

Molecule	Role	Expression change	Evidence level	Targeted by	Explanation
IL-1β	Central pathogenic driver	Elevated	established	Anakinra, Canakinumab	IL-1β is the key cytokine driving Schnitzler inflammation. Proven by the dramatic, rapid response to anakinra — symptoms resolve within hours, confirming IL-1β as the effector molecule.
NLRP3	Inflammasome sensor	Dysregulated	strong	—	NLRP3 assembles the inflammasome that activates caspase-1, which cleaves pro-IL-1β into active form. Unlike CAPS (gain-of-function mutation), no consistent NLRP3 mutation found.
MYD88	TLR signalling adaptor	L265P in ~30%	moderate	Ibrutinib (indirect)	MYD88 L265P is found in ~30% of Schnitzler patients and >90% of Waldenström's cases. Drives NF-κB activation.
NF-κB	Master transcription factor	Persistently active	strong	Bortezomib (indirect)	Convergence point — both NLRP3/IL-1β and MYD88 pathways activate NF-κB, which drives inflammatory cytokine production.
Caspase-1	IL-1β converting enzyme	Constitutively active	moderate	—	Sits between NLRP3 and IL-1β. When NLRP3 assembles, caspase-1 cleaves pro-IL-1β into mature form.
IL-6	B-cell growth factor	Elevated	strong	Tocilizumab	IL-6 promotes B-cell differentiation and IgM secretion. Consistently elevated, but IL-6 blockade (tocilizumab) gives only temporary benefit.
IL-18	NK cell activator	Elevated	moderate	—	Another inflammasome product (cleaved by caspase-1 alongside IL-1β). Elevated levels may drive IgM-producing B-cell expansion.
TNFα	Pro-inflammatory cytokine	Elevated	moderate	—	Elevated but TNF-blockers are INEFFECTIVE in Schnitzler syndrome. This tells us TNFα is a bystander, not a driver.
BTK	B-cell receptor kinase	Active	moderate	Ibrutinib	Downstream of MYD88 in B-cell signalling. Also regulates NLRP3 inflammasome. Ibrutinib (BTK inhibitor) reduces both symptoms AND IgM levels.
Gasdermin D	Membrane pore former	Active	emerging	—	Mediates IL-1β release and pyroptosis. Part of the downstream inflammasome execution pathway.
MRP8/14 (S100A8/A9)	Neutrophil inflammatory markers	Elevated	strong	—	Correlate with disease activity. Normalize with IL-1 blockade. Useful biomarkers for monitoring treatment response.
CCL2	Monocyte chemoattractant	Elevated	moderate	—	Elevated in patient serum. Produced by PBMCs and dermal fibroblasts upon IL-1β stimulation. Recruits mononuclear cells to skin and bone.
IgM (monoclonal)	Diagnostic paraprotein	Present (obligate)	established	Ibrutinib (reduces), Rituximab (reduces but ineffective on symptoms)	Obligate diagnostic criterion. Kappa light chain predominance (15:1). Relationship to inflammation is the central unsolved mystery.

Genetic Findings (6)

Gene	Variant	Type	Frequency in disease	Significance	Also found in
MYD88	L265P (somatic)	somatic	~30% of tested patients	The most significant genetic finding. Same mutation found in >90% of Waldenström's macroglobulinemia. Drives persistent NF-κB activation.	Waldenström's macroglobulinemia (>90%)
NLRP3	Somatic mosaicism (various)	somatic	Rare (2 confirmed cases)	Found in patients with the most severe phenotypes. Demonstrates that NLRP3 can be directly causative in some cases.	CAPS (Nearly all cases (germline))
NLRP3	V198M	germline	1 family studied	Found in 1 patient but 4 asymptomatic carriers across 3 generations — insufficient alone to cause disease.	CAPS (mild forms) (Occasional)
MEFV	c.2084A>G and p.(Glu148Gln)	germline	Emerging (2024-2025 reports)	MEFV encodes pyrin, an inflammasome inhibitor. Variants could lower the threshold for inflammasome activation.	Familial Mediterranean Fever (Causative (homozygous/compound het))
F2	3′UTR c.*97G>A	germline	1 case (2025)	Novel finding in the 748th reported case. F2 encodes prothrombin — role in inflammasome regulation unclear.	—
DPP10	Autoantigen target	not_found	Identified as IgM target	DPP10 identified as a reactive autoantigen for the monoclonal IgM in some patients.	—

Treatment Evidence Matrix (8 treatments)

Drug	Mechanism	Route	Response rate	Onset	IgM effect	Line	Explanation
Anakinra	IL-1 receptor antagonist	SC 100mg daily	~94%	Hours–days	No effect	1st	Blocks IL-1 receptor. Cornerstone treatment — fever and rash resolve within hours, CRP normalises within days. ~94% response across all published cases.
Canakinumab	Anti–IL-1β monoclonal antibody	SC 150mg every 4–8 weeks	High (RCT confirmed)	Days–weeks	No effect	2nd	Directly neutralises IL-1β with long half-life. The only RCT in Schnitzler demonstrated sustained efficacy.
Ibrutinib	BTK inhibitor	Oral 420mg daily	Complete in case reports	2 weeks – 3 months	Reduces IgM	Alternative	The only drug shown to reduce both inflammatory symptoms AND IgM levels. Currently limited to case reports.
Rilonacept	IL-1 decoy receptor	SC weekly	Limited data	Weeks	No effect	Alternative	Soluble decoy receptor that traps IL-1α and IL-1β. Limited case data in Schnitzler syndrome.
Tocilizumab	Anti–IL-6 receptor	SC or IV	Temporary	Weeks	Unknown	Alternative	IL-6 is elevated, but responses are generally incomplete or temporary — loss of efficacy over time.
Rituximab	Anti-CD20 (B-cell depletion)	IV infusion	Ineffective on inflammation	—	Reduces IgM	Not recommended	Depletes B cells and can reduce IgM, but doesn't control inflammatory symptoms.
Corticosteroids	Broad anti-inflammatory	Oral	Temporary, partial	Days	No effect	Not recommended	Temporary symptom relief, but disease invariably recurs on tapering.
Bortezomib	Proteasome inhibitor	SC or IV	Single case report	Unknown	Unknown	Investigational	Novel approach reported in 2024 in a patient without detectable serum IL-1β. Very preliminary.

Diagnostic Criteria

Lipsker Criteria (2001)

Sensitivity: 100% · Specificity: 97%

Major criteria (all required)

Chronic urticarial rash
Monoclonal IgM component

Minor criteria (2+ required)

Recurrent fever (>38°C)
Arthralgia or arthritis
Bone pain
Lymphadenopathy
Hepatomegaly and/or splenomegaly
Elevated ESR (>20 mm/h)
Leukocytosis (>10,000/μL)
Abnormal bone imaging findings

Both major criteria required plus ≥2 minor criteria. Validated by Gusdorf et al. 2017.

Strasbourg Criteria (2013)

Sensitivity: 81% (definite), 93% (probable) · Specificity: 100% (definite), 97% (probable)

Major criteria (all required)

Chronic urticarial rash
Monoclonal IgM OR IgG gammopathy

Minor criteria (2+ required)

Recurrent fever (>38°C)
Objective findings of abnormal bone remodeling with or without bone pain
Neutrophilic dermal infiltrate on skin biopsy
Elevated CRP and/or leukocytosis

Both obligate criteria required. For IgG variant, ≥3 minor criteria required instead of ≥2.

Differential Diagnoses (6)

Condition	Key distinction	Shared features
Adult-Onset Still's Disease	Rash is evanescent salmon-colored (not urticarial). Markedly elevated ferritin. No monoclonal gammopathy.	Quotidian fever, Arthralgia, Leukocytosis, Elevated CRP
Cryopyrin-Associated Periodic Syndromes (CAPS)	Genetic: NLRP3 germline mutations. Typically childhood onset. Family history.	Urticarial rash, Fever, IL-1β driven, Responds to IL-1 blockade
Urticarial vasculitis	Skin biopsy shows vasculitis. Individual lesions last >24 hours. Often painful.	Chronic urticarial rash, Systemic symptoms possible
Chronic spontaneous urticaria	Responds to antihistamines (Schnitzler does not). No monoclonal gammopathy.	Chronic urticarial rash
Waldenström's macroglobulinemia	Higher IgM levels. Bone marrow lymphoplasmacytic infiltration. No urticarial rash.	Monoclonal IgM, MYD88 L265P, Can develop from Schnitzler
Systemic mastocytosis	Mast cell infiltration on biopsy. Elevated serum tryptase.	Skin lesions, Systemic symptoms, Bone involvement possible

Hypotheses (7)

Hypothesis	Domain	Status	Evidence score	Studies	Evidence for	Evidence against
Shared MYD88/NF-κB mechanism drives both autoinflammation and B-cell clonality	pathogenesis	leading	55/100	48	MYD88 L265P found in ~30% of patients Same mutation in >90% of Waldenström's NF-κB drives both inflammasome priming and B-cell survival Ibrutinib controls both symptoms and IgM	70% of patients don't carry MYD88 L265P No shared clonal B-cell population across patients 32-gene sequencing found no universal genetic alteration
Independent parallel processes: inflammasome dysregulation and MGUS are separate consequences of an upstream event	pathogenesis	competing	35/100	30	No consistent correlation between IgM levels and symptom severity IL-1 blockade controls inflammation without affecting the clone Some Schnitzler-like cases lack monoclonal gammopathy entirely	Both IL-1 overproduction and IgM are universal — coincidence unlikely MYD88 L265P links both pathways in the same cells
IL-1 blockade may prevent lymphoproliferative transformation to Waldenström's	treatment	competing	30/100	12	French cohort: 2 WM cases were NOT on anakinra; 29 treated patients had no transformation Chronic inflammation may drive B-cell clone expansion	IL-1 blockade does NOT reduce monoclonal IgM levels No prospective study has tested this
Schnitzler syndrome is a spectrum, not a single disease	pathogenesis	emerging	30/100	15	IgM vs IgG variants With vs without MYD88 L265P With vs without NLRP3 mosaicism Schnitzler-like syndromes without gammopathy exist	All subtypes respond to IL-1 blockade Core clinical features are consistent
Monoclonal IgM directly triggers inflammasome activation (autoantibody model)	pathogenesis	weakening	25/100	22	IgM is universally present (obligate criterion) DPP10 identified as potential IgM target IgM deposits found in skin in some cases	Rituximab reduces IgM but doesn't control inflammation IL-1 blockade controls symptoms without affecting IgM IgM levels don't correlate with disease activity
NLRP3 somatic mosaicism is the primary driver in a subset of patients	genetics	emerging	20/100	8	Somatic NLRP3 mosaicism confirmed in 2 patients with severe phenotypes Parallels CAPS mechanism Explains inflammasome hyperactivation directly	Only 2 confirmed cases 32-gene study found no shared NLRP3 alteration
Pyrin-inflammasome dysfunction (MEFV variants) contributes to pathogenesis	genetics	emerging	15/100	4	MEFV variants found in patients from Hungary and Spain (2024-2025) MEFV encodes pyrin, which inhibits inflammasome Connects to broader autoinflammatory disease mechanisms	Common MEFV variants have low penetrance Only a few cases reported

Open Questions (6)

What is the relationship between the monoclonal gammopathy and the autoinflammation?
Three competing hypotheses exist. MYD88 L265P is the strongest candidate for a shared mechanism but is absent in ~70% of patients.
What triggers the initial inflammasome dysregulation?
No consistent genetic mutation identified. Environmental triggers? Stochastic cellular events? Epigenetic dysregulation?
Does IL-1 blockade prevent lymphoproliferative transformation?
Suggestive data from the French cohort but IL-1 therapy does not alter monoclonal component levels. Needs long-term prospective studies.
Can ibrutinib address both the inflammatory and gammopathy components simultaneously?
Only agent shown to reduce monoclonal protein AND control symptoms. Very limited data. Needs prospective trials.
Is Schnitzler syndrome truly a single disease or a spectrum?
Growing recognition of IgG variants, Schnitzler-like syndromes without gammopathy, and molecular subtypes.
What is the role of newly identified genes (MEFV, F2)?
MEFV variants found in some patients (2024-2025). MEFV encodes pyrin (inflammasome inhibitor). Significance uncertain.

Complications (3)

Complication	Risk	Timeframe	Description	Monitoring
Lymphoproliferative transformation	15-20% at 10 years	Median 8 years	Most commonly Waldenström's macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL).	Annual SPEP/immunofixation; complete blood count every 6 months
AA amyloidosis	~3-5%	Years of uncontrolled inflammation	Secondary amyloidosis due to chronic inflammation. Can cause renal failure.	Annual serum amyloid A level; renal function monitoring
Osteoporosis / pathologic fractures	Variable	—	Chronic bone inflammation can lead to structural weakening.	DEXA scan; bone scintigraphy if symptomatic

Sources (26)

Ref	Authors	Title	Journal	Year	Category	Type	Grade	Link
C7	Kanabaj K, et al.	748th case: novel MEFV and F2 gene variants	Int J Mol Sci	2025	genetics	case report	C	—
J5	Braud A, Lipsker D	Most recent comprehensive review	Biomolecules	2024	reviews	narrative review	B	—
J6	Kanabaj K, et al.	Modern look at Schnitzler syndrome	PubMed 40654214	2024	reviews	narrative review	B	—
I5	Huang Y, et al.	Ibrutinib for MYD88 L265P-positive Schnitzler	Front Immunol	2022	treatment	case report	C	—
J4	Qiao J, Yao Q	Schnitzler and Schnitzler-like syndromes review	PMC 9337259	2022	reviews	narrative review	B	—
B4	Bonnekoh H, et al.	NETosis in Schnitzler syndrome	Front Immunol	2019	pathophysiology	cohort	C	—
B7	Van Leersum FS, et al.	Shared MYD88/NF-κB mechanism hypothesis	Orphanet J Rare Dis	2019	pathophysiology	expert opinion	C	—
B3	Regnault V, et al.	PBMC studies: spontaneous IL-1β release	Scand J Rheumatol	2019	pathophysiology	cohort	C	—
C4	Pathak S, et al.	MYD88 L265P in 30% of Schnitzler patients	Exploratory study	2019	genetics	cohort	B	—
C2	Rowczenio DM, et al.	32-gene sequencing study	Blood	2018	genetics	cohort	B	—
I9	NHS England	Anakinra as first-line treatment policy	NHS England	2018	treatment	expert opinion	B	—
A6	Gusdorf L, et al.	Validation of diagnostic criteria	Allergy	2017	diagnostics	cohort	B	—
B2	de Koning HD, et al.	IL-1β centrality via canakinumab trial	Arthritis Res Ther	2015	pathophysiology	cohort	B	—
C1	de Koning HD, et al.	NLRP3 somatic mosaicism in variant Schnitzler	J Allergy Clin Immunol	2015	genetics	case series	C	—
A5	de Koning HD	Comprehensive review (281 cases)	Clin Transl Allergy	2014	reviews	narrative review	B	—
D3	Niederhauser BD, et al.	Bone imaging findings (22 patients)	Skeletal Radiol	2014	diagnostics	cohort	B	—
G5	Néel A, et al.	Multicenter anakinra study (29 patients, France)	Autoimmun Rev	2014	treatment	cohort	B	—
G6	Szturz P, et al.	Czech multicenter anakinra study (6 patients)	PubMed 24739048	2014	treatment	cohort	B	—
A4	Simon A, et al.	Strasbourg criteria for Schnitzler syndrome	Allergy	2013	diagnostics	expert opinion	B	—
E1	Jain T, et al.	Under-diagnosis at Mayo Clinic	PMC 3789463	2013	epidemiology	cohort	B	—
H1	de Koning HD, et al.	Canakinumab efficacy (9-month trial)	Ann Rheum Dis	2013	treatment	cohort	B	—
B1	Lipsker D	Schnitzler syndrome as paradigm of acquired autoinflammatory disease	Orphanet J Rare Dis	2010	pathophysiology	narrative review	B	—
A3	de Koning HD, et al.	Landmark systematic review (94 patients)	Semin Arthritis Rheum	2007	epidemiology	systematic review	B	—
G1	Martinez-Taboada VM, et al.	First successful anakinra treatment	Arthritis Rheum	2005	treatment	case report	C	—
A2	Lipsker D, et al.	Lipsker diagnostic criteria for Schnitzler syndrome	Medicine	2001	diagnostics	case series	B	—
A1	Schnitzler L, et al.	Original description of the syndrome	Bull Soc Franc Derm Syph	1974	diagnostics	case series	C	—

Pathophysiology Narrative

Schnitzler syndrome is driven by dysregulated activation of the NLRP3 inflammasome, leading to excessive IL-1β production. This central role is proven by the dramatic, rapid response to anakinra (IL-1 receptor antagonist) — symptoms resolve within hours of the first injection.

The cascade begins with inflammasome assembly: NLRP3 recruits ASC and activates caspase-1, which cleaves pro-IL-1β into its active form. IL-1β then drives all the cardinal features — urticarial rash (via neutrophil recruitment to skin), recurrent fever, bone pain/osteosclerosis, arthralgia, and elevated CRP/ESR.

What triggers the inflammasome in the first place remains unresolved. Unlike CAPS (cryopyrin-associated periodic syndromes), where gain-of-function NLRP3 mutations are causative, no consistent genetic mutation has been found in Schnitzler syndrome. MYD88 L265P — the same somatic mutation found in >90% of Waldenström's macroglobulinemia — is present in ~30% of Schnitzler patients, suggesting a shared pathogenic link via NF-κB activation. But 70% of patients don't carry it.

The relationship between the obligate monoclonal IgM gammopathy and the autoinflammation is the central mystery. Three hypotheses compete: (1) a shared MYD88/NF-κB mechanism drives both, (2) the IgM paraprotein directly triggers inflammation, (3) they are independent consequences of an upstream event. The failure of rituximab (which depletes B cells and reduces IgM but doesn't control inflammation) argues against hypothesis 2.

Genetic Basis Narrative

The genetic basis of Schnitzler syndrome remains elusive. A landmark 32-gene sequencing study (Rowczenio et al. 2018) found no shared genetic alteration across patients, distinguishing it from monogenic autoinflammatory diseases like CAPS.

The most significant finding is MYD88 L265P, a somatic mutation present in ~30% of tested Schnitzler patients (Pathak et al. 2019). This same mutation occurs in >90% of Waldenström's macroglobulinemia cases, supporting a shared pathogenic mechanism via persistent NF-κB activation.

Somatic NLRP3 mosaicism has been identified in a small number of patients with the most severe phenotypes (de Koning et al. 2015), but this is rare and not a general explanation.

Emerging evidence (2024-2025) points to MEFV gene variants in some patients. MEFV encodes pyrin, an inflammasome inhibitor — variants could theoretically lower the threshold for inflammasome activation. The F2 gene (prothrombin) has also been implicated in one case. These findings suggest Schnitzler syndrome may involve multiple genetic modifiers rather than a single causative gene.